Correlation Engine 2.0
Clear Search sequence regions


  • antibodies (2)
  • antigens cd (2)
  • antigens neoplasm (2)
  • BDNF (1)
  • CD39 (3)
  • cd39 antigen (1)
  • CD52 (7)
  • cd52 protein, human (1)
  • cytokines (2)
  • factor (3)
  • Forkhead (2)
  • Foxp3 (2)
  • GALT (1)
  • glycoproteins (2)
  • humans (1)
  • il 10 (1)
  • IL 17 (1)
  • mice (1)
  • pathogenesis (1)
  • patients (1)
  • protein human (1)
  • SMAD3 (1)
  • t lymphocytes (2)
  • Sizes of these terms reflect their relevance to your search.

    While examining the therapeutic value of anti-CD52 antibody against EAE/MS, we identified a unique subset of CD39+ Tregs in repopulating GALT tissues, a major lymphoid reservoir, which was accompanied by amelioration of disease. Furthermore, anti-CD52 treatment leads to increased expression of BDNF, IL-10, and SMAD3 in the brains of EAE mice. This condition is associated with suppression of IL-17, a critical inflammatory factor in EAE/MS progression. Additionally, we found elevated levels of CD4+CD39+ Tregs in PBMCs of RRMS patients treated with humanized anti-CD52 mAb. Thus, anti-CD52 can affect multiple immune mediated pathways involved in the pathogenesis of EAE/MS. Copyright © 2016. Published by Elsevier B.V.

    Citation

    Anudeep B Pant, Yan Wang, Daniel W Mielcarz, Eli J Kasper, Kiel M Telesford, Megan Mishra, Azizul Haque, Jacqueline Y Channon, Lloyd H Kasper, Sakhina Begum-Haque. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment. Journal of neuroimmunology. 2017 Feb 15;303:22-30

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 28087077

    View Full Text